Drug intelligence / Profile preview

GamEvac-Lyo

Development stage: Phase 2
Lead developer: Gamaleya Center
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**GamEvac-Lyo** is a lyophilized, heterologous viral-vector vaccine for prevention of Ebola virus disease. It uses recombinant vesicular stomatitis virus and recombinant human adenovirus serotype 5 vectors that express the glycoprotein of Zaire ebolavirus Makona; the prime-boost regimen is intended to induce Ebola glycoprotein-specific humoral and cellular immune responses. It was developed and manufactured by the Gamaleya Research Center and has been registered by the Russian Ministry of Health for adult Ebola prevention. ([terrance.who.int](https://terrance.who.int/mediacentre/data/sage/SAGE_Docs_Ppt_Oct2019/7_session_ebola/Oct2019_Session7_overview_candidate_EbolaVaccines.pdf))

Brand names: GamEvac-Lyo
Other names: GamEvac-Lio

Targets

Zaire ebolavirus glycoprotein

Beyond the preview

Go deeper on GamEvac-Lyo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GamEvac-Lyo.

Explore the full profile